Effect of Cariprazine on Anhedonia in Patients with Bipolar I Depression: Post Hoc Analysis of Three Randomized Placebo-Controlled Clinical Trials
Résumé
Outcomes included change from baseline to week 6 in MADRS total and anhedonia factor score, with the latter also evaluated after adjusting for other depressive symptoms. Betweengroup differences in change from baseline to week 6 were compared using least-squares mean differences (LSMD) analyzed via a mixed-effect model for repeated measures. Results: Median baseline anhedonia factor score was 19, defining the lower (placebo = 211; cariprazine 1.5 mg/day = 200, 3 mg/day = 212) and higher (placebo = 249; cariprazine 1.5 mg/ day = 261, 3 mg/day = 250) anhedonia subgroups. In the lower subgroup, cariprazine 1.5 mg/day but not 3 mg/day was superior to placebo in reducing MADRS total (LSMD [95% CI] 1.5 mg/ day = -2.61 [-4.28, -0.93], P = .0024) and anhedonia factor scores (-1.70 [-2.77, -0.62], P = .0021) at week 6. In the higher subgroup, both cariprazine doses were associated with significantly greater reductions than placebo in MADRS total (1.5 mg/day = -3.01 [-4.84, -1.19], P = .0012; 3 mg/day = -3.26 [-5.12, -1.40], P = .0006) and anhedonia factor scores (1.5 mg/ day = -1.97 [-3.13, -0.81], P = .0009; 3 mg/ day = -2.07 [-3.26, -0.89], P = .0006). Anti-anhedonic effects were preserved after adjusting for P r i o r P r e s e n t a t i o n E u r o p e a n C o l l e g e o f Neuropsychopharmacology, October 7-10, 2023, Barcelona, Spain (poster presentation).
Mots clés
Domaines
Psychiatrie et santé mentaleOrigine | Fichiers produits par l'(les) auteur(s) |
---|